Up 38% since IPO in fall 2021. Shares got killed last year during inflation and rate hikes. Has since rebounded. It's been a round trip. Their last report was solid, but guidance was ugly, given a delay in their new telemedicine product given regulatory interference. But they've beaten every quarter. Pricey at 47x PE 2023 but are profitable.
Doximity is a American stock, trading under the symbol DOCS-N on the New York Stock Exchange (DOCS). It is usually referred to as NYSE:DOCS or DOCS-N
In the last year, there was no coverage of Doximity published on Stockchase.
Doximity was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Doximity.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Doximity published on Stockchase.
On 2024-12-12, Doximity (DOCS-N) stock closed at a price of $52.7.